Patients with severe hepatic steatosis who also had thrombocytopenia were found to be at a higher risk for cardiovascular-related mortalities and all-cause mortality. The abstract was presented at the American Association for the Study of Liver Diseases' 2018 Liver Meeting.
Correctly distinguishing in vitro from in vivo hemolysis is clinically important because the latter could be a sign of various pathological conditions, including some that could be life-threatening if untreated, writes John Mitsios, assistant director of the special coagulation laboratory at BioReference Laboratories. In vivo hemolysis can be caused by several factors including blood cell defects, or autoimmune hemolytic anemia and hemolysis after an incompatible transfusion. In vitro hemolysis usually results from pre-analytical factors such as blood drawing and specimen handling.
As the number of Ebola virus infections nears 500 in the Democratic Republic of Congo, South Sudan is preparing to begin a vaccination campaign among health care workers, according to the World Health Organization. South Sudan, Uganda and Rwanda, all of which border the DRC, were identified as being "at very high risk" of Ebola by the WHO.
Researchers with the Medical University of Vienna found hepatitis C virus in the rectal and nasal fluids of patients with high viral loads, even when blood was not present in those bodily fluids. The findings were presented at a meeting of the American Association for the Study of Liver Diseases.
Egyptian Health and Population Minister Hala Zayed said that 15.5 million people have been screened for hepatitis C as part of the country's 100 Million Healthy Lives initiative. Egypt has the highest prevalence of HCV globally, and the campaign aims to screen adults ages 19 to 59.
AusDiagnostics, an Australian startup, said CE-IVD marking has been granted to its assay for hemochromatosis. The polymerase chain reaction test detects mutant and wild-type alleles of the protein hFE.
Researchers recruited 525 patients with diabetes and found that fasting-evoked en route hypoglycemia events were more likely to happen among those who fasted before a blood cholesterol test and could lead to life-threatening accidents. The findings in the International Journal of Endocrinology revealed that "FEEHD is overlooked in clinical practice, and we aim to bring this problem to light and further educate doctors and patients about the consequences of fasting while on diabetes medications," said study author Saleh Aldasouqi.
Brii Biosciences has partnered with VBI Vaccines in a development deal for VBI-2601, an injectable drug designed to strengthen immune responses to hepatitis B virus. VBI will be paid $11 million upfront plus potential milestone payments worth up to $117.5 million and royalties from sales in China, Macau, Hong Kong and Taiwan, while Brii will conduct proof-of-concept clinical studies in China.
Draft guidance is available from the FDA that aims to facilitate approval of cancer companion diagnostics for a class of drugs. The guidance may streamline treatment options for groups of targeted drugs such as PD-1/PD-L1 inhibitors and could boost development of companion diagnostics.